Pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β are being targeted by therapeutic approaches to curb the aberrant inflammatory response in IBD due to their roles in the pathogenesis of the disease [50,51,52]. This evidence concerns the gene IL6 and inflammatory bowel disease.